ABVC BioPharma, Inc. (ABVC)Healthcare | Biotechnology | Fremont, United States | NasdaqCM
1.35 USD
-0.16
(-10.596%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.34 -0.01 (-0.010%) ⇩ (July 13, 2026, 7:38 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:57 a.m. EDT
The immediate outlook is clouded by severe structural distress. The company is facing a 'going-concern' warning, has replaced its auditor, and carries a debt load nearly 13 times its cash reserves, creating a precarious balance sheet. Fundamentally, the business has suffered a catastrophic multi-year decline, dropping 99% over the last nine years, with no reported revenue and negative returns on equity and assets. While the stock recently rallied off lows, this appears to be a technical bounce rather than a recovery of business quality, especially given the negative earnings guidance. There is no dividend to provide income, and the capital structure is fragile. The recent spin-off announcement adds complexity but does not resolve the core solvency issues. For a long-term investor, the deteriorating fundamentals and existential risks make this a clear avoidance. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.147994 |
| AutoTheta | 0.154800 |
| MSTL_126 | 0.160089 |
| AutoARIMA | 0.172965 |
| MSTL | 0.173030 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 0.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.025 |
| Excess Kurtosis | 0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.29 |
| Market Cap | 35,100,596 |
| Forward P/E | -3.07 |
| Beta | 0.54 |
| Previous Name | American BriVision (Holding) Corporation |
| Website | https://www.abvcpharma.com |
As of July 11, 2026, 4:57 a.m. EDT: Speculator positioning is extremely thin and fragmented. Call volume is concentrated in near-term strikes ($2.50) with zero open interest, suggesting speculative bets rather than established positions. Put activity is negligible across all expirations, indicating a lack of hedging or bearish insurance. The absence of significant open interest at key strikes implies the market is not forming a consensus view on direction, likely due to the stock's low liquidity and micro-cap status.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.56980056 |
| Address1 | 44,370 Old Warm Springs Boulevard |
| All Time High | 7,165,605.0 |
| All Time Low | 0.343949 |
| Ask | 1.61 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 278,590 |
| Average Daily Volume3 Month | 137,881 |
| Average Volume | 137,881 |
| Average Volume10Days | 278,590 |
| Beta | 0.538 |
| Bid | 1.05 |
| Bid Size | 2 |
| Book Value | 0.43 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.35 |
| Current Ratio | 0.12 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.4878 |
| Day Low | 1.2205 |
| Debt To Equity | 21.29 |
| Display Name | ABVC BioPharma |
| Dividend Date | 1,557,273,600 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -8,006,634 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.833 |
| Enterprise Value | 38,698,864 |
| Eps Forward | -0.44 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3138 |
| Fifty Day Average Change | 0.036200047 |
| Fifty Day Average Change Percent | 0.027553696 |
| Fifty Two Week Change Percent | -56.980057 |
| Fifty Two Week High | 4.045 |
| Fifty Two Week High Change | -2.6950002 |
| Fifty Two Week High Change Percent | -0.66625464 |
| Fifty Two Week Low | 0.88 |
| Fifty Two Week Low Change | 0.47000003 |
| Fifty Two Week Low Change Percent | 0.53409094 |
| Fifty Two Week Range | 0.88 - 4.045 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,100,097,000,000 |
| Float Shares | 20,441,753 |
| Forward Eps | -0.44 |
| Forward P E | -3.068182 |
| Free Cashflow | 1,156,323 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18569 |
| Held Percent Institutions | 0.031400003 |
| Implied Shares Outstanding | 26,000,442 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,690,243,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. |
| Long Name | ABVC BioPharma, Inc. |
| Market | us_market |
| Market Cap | 35,100,596 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_325748154 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -8,626,721 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 39,260,667 |
| Open | 1.45 |
| Operating Cashflow | -3,340,709 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 668 0881 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.74074 |
| Post Market Price | 1.34 |
| Post Market Time | 1,783,985,914 |
| Prev Name | American BriVision (Holding) Corporation |
| Previous Close | 1.51 |
| Price Hint | 4 |
| Price To Book | 3.139535 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.038 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -10.596 |
| Regular Market Day High | 1.4878 |
| Regular Market Day Low | 1.2205 |
| Regular Market Day Range | 1.2205 - 1.4878 |
| Regular Market Open | 1.45 |
| Regular Market Previous Close | 1.51 |
| Regular Market Price | 1.35 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 168,992 |
| Return On Assets | -0.29006 |
| Return On Equity | -0.87782997 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 26,000,442 |
| Shares Percent Shares Out | 0.014099999 |
| Shares Short | 366,695 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 258,898 |
| Short Name | ABVC Biopharma, Inc. |
| Short Percent Of Float | 0.0173 |
| Short Ratio | 2.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | ABVC |
| Total Cash | 202,509 |
| Total Cash Per Share | 0.008 |
| Total Debt | 2,731,219 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.90349 |
| Two Hundred Day Average Change | -0.5534899 |
| Two Hundred Day Average Change Percent | -0.29077637 |
| Type Disp | Equity |
| Volume | 168,992 |
| Website | https://www.abvcpharma.com |
| Zip | 94,538 |